Pharmaceutical company Glenmark Pharmaceuticals reported on Monday the receipt of approval from the US Food & Drug Administration for its first supplemental Abbreviated New Drug Application (sANDA) for its manufacturing facility in Monroe, North Carolina.
The company added the US FDA approval covers Atovaquone and Proguanil Hydrochloride Tablets in 250 MG/100 MG and 62.5 MG/25 MG, which is the generic version of GlaxoSmithKline's Malarone (atovaquone and proguanil hydrochloride) Tablets1.
In the US, the Monroe facility is its first manufacturing site that is designed to manufacture a variety of fixed dose pharmaceutical formulations. It has invested more than USD100m into the facility, with plans for further expansion in the coming years, according to the company.
At peak capacity, the the Monroe facility is expected to produce 300-400m tablets and capsules in 20-25m vials and pre-filled syringes as well as 25-30m ampoules for inhaled formulations, stated the company.
Additionally, the company has 16 manufacturing facilities in Europe, India and the US operating under Good Manufacturing Practices (GMP) to ensure quality and safety.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial